Fucosylation is a common glycosylation type in pancreatic cancer stem cell-like phenotypes

World Journal of Gastroenterology

Volumn 21, Issue 13, 2015, Pages 3876-3887

  Terao, Naoko ^a   Takamatsu, Shinji ^a   Minehira, Tomomi ^a   Sobajima, Tomoaki ^a   Nakayama, Kotarosumitomo ^a   Kamada, Yoshihiro ^a   Miyoshi, Eiji ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

Anti cancer drug resistance; Cancer stem cells; Fucosylation; Glycosylation; Pancreatic cancer; Sphere formation

Indexed keywords

CD24 ANTIGEN; CELL SURFACE MARKER; FUCOSYLTRANSFERASE 1; FUCOSYLTRANSFERASE 2; FUCOSYLTRANSFERASE 3; FUCOSYLTRANSFERASE 4; FUCOSYLTRANSFERASE 8; GEMCITABINE; GLYCAN; GUANOSINE DIPHOSPHATE FUCOSE; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; HERMES ANTIGEN; INTERLEUKIN 6; LECTIN; MESSENGER RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; CD24 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN; DEOXYCYTIDINE; FUCOSE; FUCOSYLTRANSFERASE; GALACTOSIDE 2-ALPHA-L-FUCOSYLTRANSFERASE;

ARTICLE; CANCER STEM CELL; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; FUCOSYLATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; GLYCOSYLATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PANCREATIC CANCER CELL LINE; PHENOTYPE; PROTEIN ANALYSIS; REGULATOR GENE; UPREGULATION; ANALOGS AND DERIVATIVES; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; GENETIC TRANSFECTION; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; PANCREATIC NEOPLASMS; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIGENS, CD24; ANTIGENS, CD44; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FUCOSE; FUCOSYLTRANSFERASES; GLYCOSYLATION; HUMANS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; RNA INTERFERENCE; SPHEROIDS, CELLULAR; TRANSFECTION;

EID: 84926658767     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v21.i13.3876     Document Type: Article

References (28)

1. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111 [PMID: 11689955 DOI:10.1038/35102167].
2. Ailles LE, Weissman IL. Cancer stem cells in solid tumors. Curr Opin Biotechnol 2007; 18: 460-466 [PMID: 18023337 DOI:10.1016/j.copbio.2007.10.007].
3. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005; 5: 275-284 [PMID: 15803154 DOI:10.1038/nrc1590].
4. Singh A, Settleman J. EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-4751 [PMID: 20531305 DOI:10.1038/onc.2010.215].
5. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130 [PMID: 16514137].
6. Kim GP, Sargent DJ, Mahoney MR, Rowland KM, Philip PA, Mitchell E, Mathews AP, Fitch TR, Goldberg RM, Alberts SR, Pitot HC. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol 2009; 27: 2848-2854 [PMID: 19380443 DOI:10.1200/JCO.2008.20.4552].
7. Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010; 467: 1109-1113 [PMID: 20981101 DOI:10.1038/nature09460].
8. Moriwaki K, Okudo K, Haraguchi N, Takeishi S, Sawaki H, Narimatsu H, Tanemura M, Ishii H, Mori M, Miyoshi E. Combination use of anti-CD133 antibody and SSA lectin can effectively enrich cells with high tumorigenicity. Cancer Sci 2011; 102: 1164-1170 [PMID: 21392166 DOI:10.1111/j.1349-7006.2011.01923.x].
9. Murata K, Miyoshi E, Kameyama M, Ishikawa O, Kabuto T, Sasaki Y, Hiratsuka M, Ohigashi H, Ishiguro S, Ito S, Honda H, Takemura F, Taniguchi N, Imaoka S. Expression of N-acetylglucosaminyltransferase V in colorectal cancer correlates with metastasis and poor prognosis. Clin Cancer Res 2000; 6: 1772-1777 [PMID: 10815896].
10. Siddiqui SF, Pawelek J, Handerson T, Lin CY, Dickson RB, Rimm DL, Camp RL. Coexpression of beta1, 6-N-acetylglucosaminyltransferase V glycoprotein substrates defines aggressive breast cancers with poor outcome. Cancer Epidemiol Biomarkers Prev 2005; 14: 2517-2523 [PMID: 16284372 DOI:10.1158/1055-9965.EPI-05-0464].
11. Yamamoto E, Ino K, Miyoshi E, Shibata K, Takahashi N, Kajiyama H, Nawa A, Nomura S, Nagasaka T, Kikkawa F. Expression of N-acetylglucosaminyltransferase V in endometrial cancer correlates with poor prognosis. Br J Cancer 2007; 97: 1538-1544 [PMID: 17971775 DOI:10.1038/sj.bjc.6604044].
12. Dosaka-Akita H, Miyoshi E, Suzuki O, Itoh T, Katoh H, Taniguchi N. Expression of N-acetylglucosaminyltransferase v is associated with prognosis and histology in non-small cell lung cancers. Clin Cancer Res 2004; 10: 1773-1779 [PMID: 15014031].
13. Kuno A, Uchiyama N, Koseki-Kuno S, Ebe Y, Takashima S, Yamada M, Hirabayashi J. Evanescent-field fluorescence-assisted lectin microarray: A new strategy for glycan profiling. Nat Methods 2005; 2: 851-856 [PMID: 16278656 DOI:10.1038/nmeth803].
14. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408 [PMID: 11846609 DOI:10.1006/meth.2001.1262].
15. Matsumura K, Higashida K, Ishida H, Hata Y, Yamamoto K, Shigeta M, Mizuno-Horikawa Y, Wang X, Miyoshi E, Gu J, Taniguchi N. Carbohydrate binding specificity of a fucose-specific lectin from Aspergillus oryzae: A novel probe for core fucose. J Biol Chem 2007; 282: 15700-15708 [PMID: 17383961 DOI: 10.1074/jbc.M701195200].
16. Kobayashi Y, Tateno H, Dohra H, Moriwaki K, Miyoshi E, Hirabayashi J, Kawagishi H. A novel core fucose-specific lectin from the mushroom Pholiota squarrosa. J Biol Chem 2012; 287: 33973-33982 [PMID: 22872641 DOI:10.1074/jbc.M111.327692].
17. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007; 1: 313-323 [PMID: 18371365 DOI:10.1016/j.stem.2007.06.002].
18. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401 [PMID: 15549107 DOI:10.1038/nature03128].
19. Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cell Mol Immunol 2010; 7: 100-103 [PMID: 20154703 DOI:10.1038/cmi.2009.119].
20. Nagano O, Okazaki S, Saya H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene 2013; 32: 5191-5198 [PMID: 23334333 DOI:10.1038/onc.2012.638].
21. Cordel S, Goupille C, Hallouin F, Meflah K, Le Pendu J. Role for alpha1, 2-fucosyltransferase and histo-blood group antigen H type 2 in resistance of rat colon carcinoma cells to 5-fluorouracil. Int J Cancer 2000; 85: 142-148 [PMID: 10585597].
22. Moriwaki K, Noda K, Nakagawa T, Asahi M, Yoshihara H, Taniguchi N, Hayashi N, Miyoshi E. A high expression of GDPfucose transporter in hepatocellular carcinoma is a key factor for increases in fucosylation. Glycobiology 2007; 17: 1311-1320 [PMID: 17884843 DOI:10.1093/glycob/cwm094].
23. Narisada M, Kawamoto S, Kuwamoto K, Moriwaki K, Nakagawa T, Matsumoto H, Asahi M, Koyama N, Miyoshi E. Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem Biophys Res Commun 2008; 377: 792-796 [PMID: 18951869 DOI:10.1016/j.bbrc.2008.10.061].
24. Tateno H, Toyota M, Saito S, Onuma Y, Ito Y, Hiemori K, Fukumura M, Matsushima A, Nakanishi M, Ohnuma K, Akutsu H, Umezawa A, Horimoto K, Hirabayashi J, Asashima M. Glycome diagnosis of human induced pluripotent stem cells using lectin microarray. J Biol Chem 2011; 286: 20345-20353 [PMID: 21471226 DOI:10.1074/jbc.M111.231274].
25. Lauc G, Essafi A, Huffman JE, Hayward C, Knežević A, Kattla JJ, Polašek O, Gornik O, Vitart V, Abrahams JL, Pučić M, Novokmet M, Redžić I, Campbell S, Wild SH, Borovečki F, Wang W, Kolčić I, Zgaga L, Gyllensten U, Wilson JF, Wright AF, Hastie ND, Campbell H, Rudd PM, Rudan I. Genomics meets glycomicsthe first GWAS study of human N-Glycome identifies HNF1α as a master regulator of plasma protein fucosylation. PLoS Genet 2010; 6: e1001256 [PMID: 21203500 DOI: 10.1371/journal. pgen.1001256].
26. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S, Schmid RM, Algül H. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011; 19: 456-469 [PMID: 21481788 DOI:10.1016/j.ccr.2011.03.009].
27. Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Furuse J, Inagaki M, Higashi S, Kato H, Terao K, Ochiai A. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 2013; 108: 2063-2069 [PMID: 23591198 DOI:10.1038/bjc.2013.174].
28. Yamada D, Kobayashi S, Wada H, Kawamoto K, Marubashi S, Eguchi H, Ishii H, Nagano H, Doki Y, Mori M. Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial-mesenchymal transition and chemoresistance in biliary tract cancer. Eur J Cancer 2013; 49: 1725-1740 [PMID: 23298711 DOI: 10.1016/j.ejca.2012.12.002].